Makowska-Grzyska Magdalena, Kim Youngchang, Gorla Suresh Kumar, Wei Yang, Mandapati Kavitha, Zhang Minjia, Maltseva Natalia, Modi Gyan, Boshoff Helena I, Gu Minyi, Aldrich Courtney, Cuny Gregory D, Hedstrom Lizbeth, Joachimiak Andrzej
Center for Structural Genomics of Infectious Diseases, University of Chicago, Chicago, IL, United States of America.
Center for Structural Genomics of Infectious Diseases, University of Chicago, Chicago, IL, United States of America; Structural Biology Center, Biosciences, Argonne National Laboratory, 9700 S Cass Ave. Argonne, IL, United States of America.
PLoS One. 2015 Oct 6;10(10):e0138976. doi: 10.1371/journal.pone.0138976. eCollection 2015.
Tuberculosis (TB) remains a worldwide problem and the need for new drugs is increasingly more urgent with the emergence of multidrug- and extensively-drug resistant TB. Inosine 5'-monophosphate dehydrogenase 2 (IMPDH2) from Mycobacterium tuberculosis (Mtb) is an attractive drug target. The enzyme catalyzes the conversion of inosine 5'-monophosphate into xanthosine 5'-monophosphate with the concomitant reduction of NAD+ to NADH. This reaction controls flux into the guanine nucleotide pool. We report seventeen selective IMPDH inhibitors with antitubercular activity. The crystal structures of a deletion mutant of MtbIMPDH2 in the apo form and in complex with the product XMP and substrate NAD+ are determined. We also report the structures of complexes with IMP and three structurally distinct inhibitors, including two with antitubercular activity. These structures will greatly facilitate the development of MtbIMPDH2-targeted antibiotics.
结核病仍然是一个全球性问题,随着耐多药和广泛耐药结核病的出现,对新药的需求日益迫切。结核分枝杆菌(Mtb)的肌苷5'-单磷酸脱氢酶2(IMPDH2)是一个有吸引力的药物靶点。该酶催化肌苷5'-单磷酸转化为黄苷5'-单磷酸,同时将NAD+还原为NADH。此反应控制进入鸟嘌呤核苷酸池的通量。我们报告了十七种具有抗结核活性的选择性IMPDH抑制剂。确定了无辅基形式的MtbIMPDH2缺失突变体以及与产物XMP和底物NAD+形成复合物的晶体结构。我们还报告了与IMP和三种结构不同的抑制剂形成复合物的结构,其中包括两种具有抗结核活性的抑制剂。这些结构将极大地促进以MtbIMPDH2为靶点的抗生素的开发。